Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
27 sept. 2019 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress
20 sept. 2019 08h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Announces New Employment Inducement Grant
17 sept. 2019 16h15 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted its new...
Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
13 sept. 2019 07h30 HE
|
Adamas Pharmaceuticals, Inc.
- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 ...
Adamas Announces New Employment Inducement Grant
10 sept. 2019 16h15 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four...
Adamas Announces New Employment Inducement Grant
12 août 2019 17h07 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Reports Second Quarter 2019 Financial Results
08 août 2019 16h02 HE
|
Adamas Pharmaceuticals, Inc.
- Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with...
Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
23 juil. 2019 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday,...
Adamas Announces New Employment Inducement Grant
08 juil. 2019 16h29 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Disease
18 juin 2019 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...